Search
This position statement, updated from the 2015 guidelines for managing Australian and New Zealand children/adolescents and adults with chronic suppurative lung disease (CSLD) and bronchiectasis, resulted from systematic literature searches by a multi-disciplinary team that included consumers.
Examine the reliability of field-based fitness assessments in school-aged children with emotional or behavioral difficulties (EBD). Understanding the impact of fitness on physical activity participation for children with EBD is limited by our ability to reliably measure it.
Determine if exercise interventions, beyond what is already provided to children and preschool children, improve bone health and reduce fracture incidence.
Childhood obesity and physical inactivity are two of the most significant modifiable risk factors for the prevention of non-communicable diseases. Yet, a third of children in Wales and Australia are overweight or obese, and only 20% of UK and Australian children are sufficiently active.
Today, on World Down Syndrome Day, we celebrate the lives, achievements, and invaluable contributions of people with Down syndrome.
Western Australia’s biggest and only medical research institute dedicated to improving kids’ health and wellbeing has rebranded to The Kids Research Institute Australia.
Congratulations to four outstanding early-career researchers from The Kids Research Institute Australia, who have been awarded BrightSpark Foundation fellowships and project funding for 2026.
Invasive pulmonary aspergillosis remains a major cause of morbidity and mortality for immunocompromised children, particularly for patients with acute leukaemia and those undergoing haematopoietic stem cell transplantation. Timely diagnosis, using a combination of computed tomography (CT) imaging and microbiological testing, is key to improve prognosis, yet there are inherent challenges in this process. For CT imaging, changes in children are generally less specific than those reported in adults and recent data are limited.
Following reduction of public health and social measures concurrent with SARS-CoV-2 Omicron emergence in late 2021 in Australia, COVID-19 case notification rates rose rapidly. As rates of direct viral testing and reporting dropped, true infection rates were most likely to be underestimated.
In mid-2018, the Australian childhood 13-valent pneumococcal conjugate vaccine schedule changed from 3+0 to 2+1, moving the third dose to 12 months of age, to address increasing breakthrough cases of invasive pneumococcal disease (IPD), predominantly in children aged >12 months. This study assessed the impact of this change using national IPD surveillance data.